<unk>  is a BRAF Inhibitor that is FDA approved for the treatment of malignant melanoma.   Common adverse reactions include peripheral edema, alopecia, hyperkeratosis, abdominal pain, constipation, anemia, arthralgia, cough.
Dabrafenib mesylate
Fostamatinib
Neratinib
Dasatinib
Encorafenib
Afatinib
Erdafitinib
Sunitinib